Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | USP5 | P45974 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12307852 | 0.91 | GRM5 (0.35) | KMT2AGRM5ITGB3ITGA2BAOC3 | |
| SCHEMBL12334297 | 0.90 | PTPRC (0.33) | POLBAOC3 | |
| SCHEMBL12334429 | 0.89 | KCNH2 (0.33) | KMT2AGRM5AOC3KCNH2HRH3 | |
| SCHEMBL12307906 | 0.89 | GRM5 (0.33) | KMT2AGRM5AOC3 | |
| SCHEMBL12335660 | 0.89 | MEN1 (0.35) | POLBKMT2AAOC3 | |
| SCHEMBL12307866 | 0.88 | FLT3 (0.33) | GRM5ITGB3ITGA2BAOC3 | |
| SCHEMBL12308000 | 0.87 | GRM5 (0.36) | KMT2AGRM5ITGB3ITGA2BDPP4 | |
| SCHEMBL12307917 | 0.87 | KCNH2 (0.32) | GRM5AOC3KCNH2HRH3 | |
| SCHEMBL12334737 | 0.87 | KCNH2 (0.36) | KMT2AGRM5AOC3KCNH2HRH3 | |
| SCHEMBL12307824 | 0.87 | NPC1 (0.38) | POLBKMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R5, PIK3R4, PIK3R1 | POLB 3114/4885KMT2A 2170/4885TDP1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.